Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer

NCT03639246 is registered in ClinicalTrials.gov with Aravive, Inc. as lead sponsor.

NCT NCT03639246
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03639246 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Randomized, Controlled Study of AVB-S6-500 in Combination With Pegylated Liposomal Doxorubicin (PLD) or Paclitaxel (Pac) in Patients With Platinum-resistant Recurrent Ovarian Cancer
Lead sponsor
Aravive, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 6, 2018
Completion date
December 30, 2022
Enrollment
53 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer